SCHEDULE: FMR LLC Discloses 7.1% Stake in IMMUNOME INC

FMR LLC and Abigail P. Johnson have disclosed a 7.1% beneficial ownership stake in IMMUNOME INC's common stock as of June 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively reported beneficial ownership of 6,167,666 shares of IMMUNOME INC's common stock.
• This aggregate amount represents 7.1% of the total outstanding common stock of IMMUNOME INC.
• FMR LLC holds sole voting power over 6,166,271 shares and sole dispositive power over 6,167,666 shares.
• Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, is deemed to beneficially own the same 6,167,666 shares with sole dispositive power.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The disclosure of a significant stake by a prominent institutional investor like FMR LLC is generally viewed positively by the market, indicating institutional confidence in the company. However, as a passive ownership filing, it does not provide operational or financial performance details to warrant a higher sentiment score.

Positives

• The disclosure of a significant 7.1% stake by a major institutional investor like FMR LLC signals confidence in IMMUNOME INC's prospects.
• The filing indicates that the shares are held in the ordinary course of business, suggesting a long-term investment perspective rather than an activist intent.

Risks

• The filing explicitly states that the securities were not acquired or held for the purpose of changing or influencing the control of the issuer, mitigating immediate control-related risks.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding IMMUNOME INC's operational or financial performance.

Industry Context

FMR LLC, as the parent company of Fidelity Investments, is one of the largest and most respected asset management firms globally. Its disclosure of a significant stake in IMMUNOME INC, a biotechnology company, highlights continued institutional interest in the life sciences sector, particularly in companies with potential for growth or innovation.

Stakeholder Impact

• Shareholders may view the significant institutional investment by FMR LLC as a positive signal, potentially increasing investor confidence and attracting further institutional interest.

Key Dates

Recommendation

While the disclosure of a significant stake by a reputable institutional investor like FMR LLC is a positive indicator of confidence in IMMUNOME INC, this Schedule 13G filing alone does not provide sufficient operational, financial, or strategic details to warrant a 'buy' or 'sell' recommendation. It primarily serves as a transparency filing regarding ownership. Investors should consider this information alongside the company's financial performance, pipeline developments, and broader market conditions.

Keywords

IMMUNOME INC, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Biotechnology